Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-α) treatment

Clinical Microbiology and Infection

Volumn 13, Issue 10, 2007, Pages 1036-1037

  Mancini, G ^a   Erario, L ^a   Gianfreda, R ^a   Oliva, A ^a   Massetti, A P ^a   Mastroianni, Claudio M ^a   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; LEVOFLOXACIN; METHOTREXATE; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; BEHCET DISEASE; CASE REPORT; CONFUSION; DYSPNEA; FEVER; HUMAN; LEGIONELLA PNEUMOPHILA; LETTER; LEUKAPHERESIS; LUNG TUBERCULOSIS; MALE; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT; UVEITIS; VOMITING;

LEGIONELLA PNEUMOPHILA;

EID: 34548539689     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01796.x     Document Type: Letter

References (7)

1. Moiton MP, Richez C, Dumoulin C, Mehsen N, Dehais J, Schaeverbeke T. Role of anti-tumour necrosis factor-α therapeutic agents in the emergence of infections. Clin Microbiol Infect 2006; 12: 1151-1153.
2. Strangfeld A, Listing J. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006; 20: 1181-1195.
3. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-610.
4. Dixon WG, Watson K, Lunt M et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376.
5. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155.
6. Tubach F, Ravaud P, Salmon-Ceron D et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-α antagonists. Clin Infect Dis 2006; 43: E95-100.
7. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.